Fig. 5From: Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysisSensitivity analysis of OS was employed to explore sources of heterogeneity. Heterogeneity declined from I2 = 27% to I2 = 0% when the study performed by Noda et al. was excludedBack to article page